866848-94-4

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-1,1-(ethylenedioxo)-indane is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and reactivity.
Used in Agrochemical Industry:
6-Bromo-1,1-(ethylenedioxo)-indane is used as a building block for the development of agrochemicals, contributing to the creation of effective and targeted pest control solutions.
Used in Chemical Research:
6-Bromo-1,1-(ethylenedioxo)-indane is used as a reagent in chemical research, aiding in the discovery and development of new compounds and materials.
Used in Anti-tumor Applications:
6-Bromo-1,1-(ethylenedioxo)-indane has been studied as a potential anti-tumor agent, showing promising activity in inhibiting the growth of cancer cells.
Used in Material Development:
6-Bromo-1,1-(ethylenedioxo)-indane has been investigated for its potential use in the development of new types of materials, leveraging its unique chemical properties.
Note: Due to its synthetic nature and potential health hazards, proper safety precautions should be taken when handling and using 6-Bromo-1,1-(ethylenedioxo)-indane.

Upstream product

• 14548-39-1 6-bromoindan-1-one 
• 107-21-1 ethylene glycol 

Downstream Products

• 954238-34-7 2',3'-dihydrospiro[[1,3]dioxolane-2,1'-indene]-6'-carbaldehyde 
• 60031-08-5 Indan-1-one-6-carboxylic acid 
• 866849-00-5 (2',3'-dihydrospiro[[1,3]dioxolane-2,1'-indene]-6'-yl)methanol 
• 193819-51-1 6-(hydroxymethyl)-1-indanone 

Relevant academic research and scientific papers

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF

The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.

Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition

The optimization, based on computational, thermodynamic, and crystallographic data, of a series of small-molecule ligands of the Phe43 cavity of the envelope glycoprotein gp120 of human immunodeficiency virus (HIV) has been achieved. Importantly, biological evaluation revealed that the small-molecule CD4 mimics (4-7) inhibit HIV-1 entry into target cells with both significantly higher potency and neutralization breadth than previous congeners, while maintaining high selectivity for the target virus. Their binding mode was characterized via thermodynamic and crystallographic studies.

Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors

A series of 1,4-dihydroindeno[1,2-c]pyrazoles was prepared and evaluated for their enzymatic inhibition of KDR kinase. Computer modeling studies revealed the importance of attaching a basic side chain in predicting the binding mode of those compounds. Fur

TRICYCLIC PYRAZOLE KINASE INHIBITORS

Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.